Free CME from PeerView
Continuing Pharmacy Education (CPE) Activities
Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular Therapy
StartThis activity expired on July 11, 2023; credit is no longer available.
Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular Therapy
Media: Enduring Material
Activity Release Date: July 12, 2022
Activity Expiration Date: July 11, 2023
Time to Complete Activity: 60 minutes
Activity Description
The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further development of immunotherapeutics, including antibody-based agents directed against targets such as CD38 and BCMA, as well as emerging BCMA CAR-T cell therapy options. These new “ABCs” of myeloma management now represent the cornerstone of high-quality, collaborative care. In this video activity, a hematologist-oncologist and an oncology nurse will highlight the importance of interprofessional collaboration when applying the new "ABCs" of patient management in MM while addressing safety and efficacy evidence supporting the use of antibodies and cellular therapy.
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, oncology nurses, advanced practice clinicians, pharmacists, and other clinicians involved in the care of patients with multiple myeloma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize current evidence surrounding novel and emerging immunotherapeutics, including antibody-based and CAR-T options, for the treatment of multiple myeloma (MM)
- Integrate novel antibody and cellular therapies into team management plans for patients with newly diagnosed or relapsed MM
- Develop team-based management plans for addressing practical dosing/schedule, safety, care coordination, and patient counseling considerations associated with the use of antibody- and cell therapy-based options in the MM setting
Accreditation, Support, and Credit
 |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Sanofi Genzyme.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
 |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-054-H01-P
Type of Activity: Knowledge
Interprofessional Continuing Education (IPCE) Statement
 |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Faculty Disclosures
Chair/Planner
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Sagar Lonial, MD, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Bristol Myers Squibb;
Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.;
Karyopharm; Novartis Pharmaceuticals Corporation; Takeda Pharmaceutical
Company Limited; and TG Therapeutics.
Grant/Research Support from Bristol Myers Squibb; Celgene
Corporation; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company
Limited.
Stock Shareholder in TG Therapeutics.
Faculty/Planner
Charise Gleason, MSN, NP-C, AOCNP
Advanced Practice Provider Chief
Winship Cancer Institute
Emory University School of Medicine
Adjunct Faculty Nell Hodgson Woodruff School of Nursing
Atlanta, Georgia
Charise Gleason, MSN, NP-C, AOCNP, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for Pfizer.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity's topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on July 11, 2023; credit is no longer available.
Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular Therapy
Media: Enduring Material
Activity Release Date: July 12, 2022
Activity Expiration Date: July 11, 2023
Time to Complete Activity: 60 minutes
Activity Description
The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further development of immunotherapeutics, including antibody-based agents directed against targets such as CD38 and BCMA, as well as emerging BCMA CAR-T cell therapy options. These new “ABCs” of myeloma management now represent the cornerstone of high-quality, collaborative care. In this video activity, a hematologist-oncologist and an oncology nurse will highlight the importance of interprofessional collaboration when applying the new "ABCs" of patient management in MM while addressing safety and efficacy evidence supporting the use of antibodies and cellular therapy.
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, oncology nurses, advanced practice clinicians, pharmacists, and other clinicians involved in the care of patients with multiple myeloma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize current evidence surrounding novel and emerging immunotherapeutics, including antibody-based and CAR-T options, for the treatment of multiple myeloma (MM)
- Integrate novel antibody and cellular therapies into team management plans for patients with newly diagnosed or relapsed MM
- Develop team-based management plans for addressing practical dosing/schedule, safety, care coordination, and patient counseling considerations associated with the use of antibody- and cell therapy-based options in the MM setting
Accreditation, Support, and Credit
|
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Sanofi Genzyme.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
|
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-054-H01-P
Type of Activity: Knowledge
Interprofessional Continuing Education (IPCE) Statement
|
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Faculty Disclosures
Chair/Planner
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Sagar Lonial, MD, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Bristol Myers Squibb;
Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.;
Karyopharm; Novartis Pharmaceuticals Corporation; Takeda Pharmaceutical
Company Limited; and TG Therapeutics.
Grant/Research Support from Bristol Myers Squibb; Celgene
Corporation; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company
Limited.
Stock Shareholder in TG Therapeutics.
Faculty/Planner
Charise Gleason, MSN, NP-C, AOCNP
Advanced Practice Provider Chief
Winship Cancer Institute
Emory University School of Medicine
Adjunct Faculty Nell Hodgson Woodruff School of Nursing
Atlanta, Georgia
Charise Gleason, MSN, NP-C, AOCNP, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for Pfizer.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity's topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
Increasing PrEP Uptake and Confident Use for HIV Prevention in Diverse Communities
StartThis activity expired on June 20, 2023; credit is no longer available.
Increasing PrEP Uptake and Confident Use for HIV Prevention in Diverse Communities
Media: Enduring Material
Activity Release Date: June 21, 2022
Activity Expiration Date: June 20, 2023
Time to Complete Activity: 30 minutes
Activity Description
In this activity, an expert in infectious diseases and a collection of individuals at risk for being exposed to HIV describe the benefits of pre-exposure prophylaxis (PrEP), particularly with diverse communities and vulnerable populations such as Black women, same gender-loving Black and/or Latinx men, and transgender men and women.
Target Audience
This activity has been designed to meet the educational needs of HIV specialty care providers, primary care providers, and general practitioners (MD/DO, NP, PA), as well as other workforce professionals (nurses, pharmacists, social workers, case managers, certified health educators, and community health workers), involved in the care of people at risk for being exposed HIV.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Incorporate clinical data on pre-exposure prophylaxis (PrEP) for HIV into culturally competent educational and counseling strategies to improve the uptake of PrEP in vulnerable populations, including Black women, Black/Latinx same-gender loving men, and transgender men and women
- Facilitate access to PrEP among Black women, Black/Latinx same-gender loving men, and transgender men and women
- Use PrEP as part of a broader strategy to reduce disparities in HIV incidence in Black women, Black/Latinx same-gender loving men, and transgender men and women
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
David Alain Wohl, MD
Professor of Medicine, Division of Infectious Diseases
Site Leader, Global Clinical Trials Unit
The University of North Carolina
Chapel Hill, North Carolina
David Alain Wohl, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Janssen
Pharmaceuticals, Inc.; Merck & Co., Inc.; and ViiV Healthcare.
Grant/Research Support from Gilead Sciences, Inc. and Merck & Co.,
Inc.
Patient/Planner
Benneth Chukwu
Benneth Chukwu has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
Taylor Chandler Walker, BC-TCT
Taylor Chandler Walker, BC-TCT, has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
Omar Martinez, JD, MPH, MS
Omar Martinez, JD, MPH, MS, has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
 |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
|
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-027-H02-P
Type of Activity: Knowledge
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright B) 2000-2022, PeerView
This activity expired on June 20, 2023; credit is no longer available.
Increasing PrEP Uptake and Confident Use for HIV Prevention in Diverse Communities
Media: Enduring Material
Activity Release Date: June 21, 2022
Activity Expiration Date: June 20, 2023
Time to Complete Activity: 30 minutes
Activity Description
In this activity, an expert in infectious diseases and a collection of individuals at risk for being exposed to HIV describe the benefits of pre-exposure prophylaxis (PrEP), particularly with diverse communities and vulnerable populations such as Black women, same gender-loving Black and/or Latinx men, and transgender men and women.
Target Audience
This activity has been designed to meet the educational needs of HIV specialty care providers, primary care providers, and general practitioners (MD/DO, NP, PA), as well as other workforce professionals (nurses, pharmacists, social workers, case managers, certified health educators, and community health workers), involved in the care of people at risk for being exposed HIV.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Incorporate clinical data on pre-exposure prophylaxis (PrEP) for HIV into culturally competent educational and counseling strategies to improve the uptake of PrEP in vulnerable populations, including Black women, Black/Latinx same-gender loving men, and transgender men and women
- Facilitate access to PrEP among Black women, Black/Latinx same-gender loving men, and transgender men and women
- Use PrEP as part of a broader strategy to reduce disparities in HIV incidence in Black women, Black/Latinx same-gender loving men, and transgender men and women
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
David Alain Wohl, MD
Professor of Medicine, Division of Infectious Diseases
Site Leader, Global Clinical Trials Unit
The University of North Carolina
Chapel Hill, North Carolina
David Alain Wohl, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Janssen
Pharmaceuticals, Inc.; Merck & Co., Inc.; and ViiV Healthcare.
Grant/Research Support from Gilead Sciences, Inc. and Merck & Co.,
Inc.
Patient/Planner
Benneth Chukwu
Benneth Chukwu has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
Taylor Chandler Walker, BC-TCT
Taylor Chandler Walker, BC-TCT, has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
Omar Martinez, JD, MPH, MS
Omar Martinez, JD, MPH, MS, has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
|
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
|
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-027-H02-P
Type of Activity: Knowledge
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright B) 2000-2022, PeerView
The Power of Team-Based Care and Novel Therapies in Alopecia Areata and Atopic Dermatitis: What Advanced Care Providers Need to Know
StartThis activity expired on June 16, 2023; credit is no longer available.
The Power of Team-Based Care and Novel Therapies in Alopecia Areata and Atopic Dermatitis: What Advanced Care Providers Need to Know
Media: Enduring Material
Activity Release Date: June 17, 2022
Activity Expiration Date: June 16, 2023
Time to Complete Activity: 60 minutes
Activity Description
Listen to our expert faculty as they discuss new and emerging therapies
for AA and AD, with a focus on mechanisms of action, efficacy and safety
profiles, nuances of administration and use, and risk:benefit profile. You
will also hear about novel therapies in late-stage development for the
treatment of moderate to severe AD and AA.
The Late Night inExchange format is designed to meet the educational needs of
clinicians with practice-relevant education presented in an engaging
multi-faculty discussion format that brings knowledge to life. Through this
format, learners will be better able to see how conceptual knowledge of AA
and AD translates to actual practice.
Target Audience
This activity has been designed to meet the educational needs of nurses, nurse practitioners, physician assistants, and primary care providers involved in the care and treatment of patients with AD and AA.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Appropriately assess the severity of atopic dermatitis (AD) and alopecia areata (AA) to determine the best treatment strategy in individual patients, recognizing wide variation in clinical presentation among different ethnicities.
- Describe advances in understanding of AD and AA pathophysiology that have led to the development of therapies with specific molecular targets.
- Assess new and emerging treatments for AD and AA in terms of their mechanisms of action, efficacy and safety profiles, nuances of administration and use, and other factors relevant to the benefit:risk profile.
- Employ a holistic and team-based healthcare approach to the management of AD and AA that addresses both the physical and psychological comorbidities of disease.
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP
VA Portland Health Care System
Dermatology Service
NP Residency Director
Portland, Oregon
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics;
Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen
Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; Regeneron
Pharmaceuticals Inc.; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries
Ltd.; and UCB, Inc.
Speakers Bureau participant with AbbVie Inc.; Janssen
Pharmaceuticals, Inc.; Lilly; Regeneron Pharmaceuticals Inc.; sanofi-aventis
U.S. LLC; Sun Pharmaceutical Industries Ltd.; and UCB, Inc.
Faculty/Planner
Lawrence Eichenfield, MD
Distinguished Professor of Dermatology and Pediatrics
Chief, Pediatric and Adolescent Dermatology
Vice Chair, Department of Dermatology
University of California
Rady Children’s Hospital
San Diego, California
Lawrence Eichenfield, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Almirall, LLC; Arcutis
Biotherapeutics; Arena Pharmaceuticals, Inc.; ASLAN Pharmaceuticals Pte Ltd;
Dermata Therapeutics, Inc.; Dermavant Sciences, Inc.; Incyte; LEO Pharma
Inc.; Lilly; Ortho Dermatologics; Otsuka America Pharmaceutical, Inc.;
Pfizer; Reistone Biopharma; and Sanofi/Regeneron Pharmaceuticals Inc.
Grant/Research Support from AbbVie Inc.; Arcutis Biotherapeutics;
Dermavant Sciences, Inc.; Ortho Dermatologics; and Pfizer.
Speakers Bureau participant with Almirall, LLC; Pfizer; and
Sanofi/Regeneron Pharmaceuticals Inc.
Stock Shareholder in Dermata Therapeutics, Inc.; Forte Biosciences,
Inc.; and Verrica Pharmaceuticals.
Other Financial or Material Support as an executive role (Board of
Directors) for Forte Biosciences, Inc. and Verrica Pharmaceuticals.
Faculty/Planner
Charles Vega, MD, FAAFP
Health Sciences Clinical Professor
UC Irvine Department of Family Medicine
Assistant Dean for Culture and Community Education
UC Irvine School of Medicine
Director
UC Irvine Program in Medical Education for the Latino Community
(PRIME-LC)
Santa Ana, California
Charles Vega, MD, FAAFP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for GlaxoSmithKline and Johnson & Johnson
Services, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
|
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Pfizer.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
|
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-023-H01-P
Type of Activity: Knowledge
Interprofessional Continuing Education (IPCE) Statement
|
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on June 16, 2023; credit is no longer available.
The Power of Team-Based Care and Novel Therapies in Alopecia Areata and Atopic Dermatitis: What Advanced Care Providers Need to Know
Media: Enduring Material
Activity Release Date: June 17, 2022
Activity Expiration Date: June 16, 2023
Time to Complete Activity: 60 minutes
Activity Description
Listen to our expert faculty as they discuss new and emerging therapies
for AA and AD, with a focus on mechanisms of action, efficacy and safety
profiles, nuances of administration and use, and risk:benefit profile. You
will also hear about novel therapies in late-stage development for the
treatment of moderate to severe AD and AA.
The Late Night inExchange format is designed to meet the educational needs of
clinicians with practice-relevant education presented in an engaging
multi-faculty discussion format that brings knowledge to life. Through this
format, learners will be better able to see how conceptual knowledge of AA
and AD translates to actual practice.
Target Audience
This activity has been designed to meet the educational needs of nurses, nurse practitioners, physician assistants, and primary care providers involved in the care and treatment of patients with AD and AA.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Appropriately assess the severity of atopic dermatitis (AD) and alopecia areata (AA) to determine the best treatment strategy in individual patients, recognizing wide variation in clinical presentation among different ethnicities.
- Describe advances in understanding of AD and AA pathophysiology that have led to the development of therapies with specific molecular targets.
- Assess new and emerging treatments for AD and AA in terms of their mechanisms of action, efficacy and safety profiles, nuances of administration and use, and other factors relevant to the benefit:risk profile.
- Employ a holistic and team-based healthcare approach to the management of AD and AA that addresses both the physical and psychological comorbidities of disease.
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP
VA Portland Health Care System
Dermatology Service
NP Residency Director
Portland, Oregon
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics;
Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen
Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; Regeneron
Pharmaceuticals Inc.; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries
Ltd.; and UCB, Inc.
Speakers Bureau participant with AbbVie Inc.; Janssen
Pharmaceuticals, Inc.; Lilly; Regeneron Pharmaceuticals Inc.; sanofi-aventis
U.S. LLC; Sun Pharmaceutical Industries Ltd.; and UCB, Inc.
Faculty/Planner
Lawrence Eichenfield, MD
Distinguished Professor of Dermatology and Pediatrics
Chief, Pediatric and Adolescent Dermatology
Vice Chair, Department of Dermatology
University of California
Rady Children’s Hospital
San Diego, California
Lawrence Eichenfield, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Almirall, LLC; Arcutis
Biotherapeutics; Arena Pharmaceuticals, Inc.; ASLAN Pharmaceuticals Pte Ltd;
Dermata Therapeutics, Inc.; Dermavant Sciences, Inc.; Incyte; LEO Pharma
Inc.; Lilly; Ortho Dermatologics; Otsuka America Pharmaceutical, Inc.;
Pfizer; Reistone Biopharma; and Sanofi/Regeneron Pharmaceuticals Inc.
Grant/Research Support from AbbVie Inc.; Arcutis Biotherapeutics;
Dermavant Sciences, Inc.; Ortho Dermatologics; and Pfizer.
Speakers Bureau participant with Almirall, LLC; Pfizer; and
Sanofi/Regeneron Pharmaceuticals Inc.
Stock Shareholder in Dermata Therapeutics, Inc.; Forte Biosciences,
Inc.; and Verrica Pharmaceuticals.
Other Financial or Material Support as an executive role (Board of
Directors) for Forte Biosciences, Inc. and Verrica Pharmaceuticals.
Faculty/Planner
Charles Vega, MD, FAAFP
Health Sciences Clinical Professor
UC Irvine Department of Family Medicine
Assistant Dean for Culture and Community Education
UC Irvine School of Medicine
Director
UC Irvine Program in Medical Education for the Latino Community
(PRIME-LC)
Santa Ana, California
Charles Vega, MD, FAAFP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for GlaxoSmithKline and Johnson & Johnson
Services, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
|
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Pfizer.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
|
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-023-H01-P
Type of Activity: Knowledge
Interprofessional Continuing Education (IPCE) Statement
|
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
New Rules for Sequential Care in BRAF-Mutated Melanoma: Rethinking Upfront Selection and Sequencing of Immunotherapy and Targeted Agents in Metastatic Disease
StartThis activity expired on July 3, 2023; credit is no longer available.
New Rules for Sequential Care in BRAF-Mutated Melanoma: Rethinking Upfront Selection and Sequencing of Immunotherapy and Targeted Agents in Metastatic Disease
Media: Enduring MaterialActivity Release Date: June 4, 2022
Activity Expiration Date: July 3, 2023
Time to Complete Activity: 60 minutes
Activity Description
Treatment advances in metastatic melanoma have been characterized by the use of immunotherapy, including PD-1 and CTLA-4 checkpoint inhibitors, as well as targeted agents in BRAF-mutated disease—and collectively these modalities represent the driving forces leading to improved clinical outcomes across disease settings. How will new evidence change this current paradigm? In this MasterClass & Case Forum video activity, based on a live event at the 2022 ASCO Annual Meeting, an expert panel explores the latest practice-changing clinical evidence for managing BRAF-mutated melanoma, while providing case-based practical guidance on modern treatment decisions with immunotherapy and targeted agents. Learn how these experts are using novel immune-based options in this setting to improve outcomes for their patients with BRAF-mutated disease.Target Audience
This activity has been designed to meet the educational needs of oncologists, advanced practice providers, nurses, pharmacists, and other healthcare professionals involved in the care of patients with melanoma.Educational Objectives
Upon completion of this activity, participants should be better able to:- Cite current evidence on the efficacy of modern sequential approaches to using immunotherapy and targeted regimens in the setting of BRAF-mutated, metastatic melanoma
- Utilize optimized strategies with immunotherapy components for the initial and sequential management of patients with BRAF-mutated, metastatic melanoma
- Develop team-based, collaborative strategies for managing toxicity associated with the sequential use of immunotherapy and targeted agents in patients with metastatic melanoma
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner Disclosures
Chair/PlannerHussein A. Tawbi, MD, PhD
Deputy Chair and Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Hussein A. Tawbi, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Dragonfly Therapeutics, Inc.; Eisai, Inc.; EMD Serono; Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and RAPT Therapeutics.
Grant/Research Support from Boxer Capital, LLC.; Bristol Myers Squibb; Eisai, Inc.; Genentech, Inc.; Iovance Biotherapeutics; Jazz Pharmaceuticals, Inc.; Karyopharm Therapeutics; Medicenna; Merck & Co., Inc.; and Novartis Pharmaceuticals Corporation.
Faculty/Planner
Caroline Robert, MD, PhD
Head, Dermatology Unit
Director, Melanoma Research Team at INSERM U981
Gustave Roussy and Paris Saclay University
Villejuif, France
Caroline Robert, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; F. Hoffmann-La Roche Ltd.; MSD; Novartis Pharmaceuticals Corporation; Pierre Fabre Group; Pfizer; and Sanofi.
Faculty/Planner
Ahmad A. Tarhini, MD, PhD
Senior Member, Departments of Cutaneous Oncology & Immunology
H. Lee Moffitt Cancer Center & Research Institute
Professor, Department of Oncologic Sciences
University of South Florida Morsani College of Medicine
Chair, ORIEN Scientific Committee & ImmunoOncology Research Subcommittee
Tampa, Florida
Ahmad A. Tarhini, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for BioNTech SE; Bristol Myers Squibb; Clinigen Limited; Eisai, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Instil Bio; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Partner Therapeutics, Inc.; Regeneron Pharmaceuticals Inc.; and Sanofi.
Grant/Research Support from Acrotech Biopharma; Agenus Inc.; Bristol Myers Squibb; Checkmate Pharmaceuticals; Clinigen Limited; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Nektar Therapeutics; OncoSec Medical Incorporated; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute
for Medical Education, is jointly accredited by the Accreditation Council for
Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy
Education (ACPE), and the American Nurses Credentialing Center (ANCC), to
provide continuing education for the healthcare team.Support
This activity is supported through an educational grant from Bristol Myers Squibb.Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.MOC Statement
Successful completion of this CME activity, which includes
participation in the evaluation component, enables the participant to earn up
to 1.0 MOC points and patient safety MOC credit in the American Board of
Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is
the CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.Universal Activity Number: JA4008289-0000-22-012-H01-P
Type of Activity: Knowledge
Interprofessional Continuing Education (IPCE) Statement
This
activity was planned by and for the healthcare team, and learners will
receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning
and change.Method of Participation
There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.Copyright © 2000-2022, PeerView
This activity expired on July 3, 2023; credit is no longer available.
New Rules for Sequential Care in BRAF-Mutated Melanoma: Rethinking Upfront Selection and Sequencing of Immunotherapy and Targeted Agents in Metastatic Disease
Media: Enduring MaterialActivity Release Date: June 4, 2022
Activity Expiration Date: July 3, 2023
Time to Complete Activity: 60 minutes
Activity Description
Treatment advances in metastatic melanoma have been characterized by the use of immunotherapy, including PD-1 and CTLA-4 checkpoint inhibitors, as well as targeted agents in BRAF-mutated disease—and collectively these modalities represent the driving forces leading to improved clinical outcomes across disease settings. How will new evidence change this current paradigm? In this MasterClass & Case Forum video activity, based on a live event at the 2022 ASCO Annual Meeting, an expert panel explores the latest practice-changing clinical evidence for managing BRAF-mutated melanoma, while providing case-based practical guidance on modern treatment decisions with immunotherapy and targeted agents. Learn how these experts are using novel immune-based options in this setting to improve outcomes for their patients with BRAF-mutated disease.Target Audience
This activity has been designed to meet the educational needs of oncologists, advanced practice providers, nurses, pharmacists, and other healthcare professionals involved in the care of patients with melanoma.Educational Objectives
Upon completion of this activity, participants should be better able to:- Cite current evidence on the efficacy of modern sequential approaches to using immunotherapy and targeted regimens in the setting of BRAF-mutated, metastatic melanoma
- Utilize optimized strategies with immunotherapy components for the initial and sequential management of patients with BRAF-mutated, metastatic melanoma
- Develop team-based, collaborative strategies for managing toxicity associated with the sequential use of immunotherapy and targeted agents in patients with metastatic melanoma
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner Disclosures
Chair/PlannerHussein A. Tawbi, MD, PhD
Deputy Chair and Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Hussein A. Tawbi, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Dragonfly Therapeutics, Inc.; Eisai, Inc.; EMD Serono; Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and RAPT Therapeutics.
Grant/Research Support from Boxer Capital, LLC.; Bristol Myers Squibb; Eisai, Inc.; Genentech, Inc.; Iovance Biotherapeutics; Jazz Pharmaceuticals, Inc.; Karyopharm Therapeutics; Medicenna; Merck & Co., Inc.; and Novartis Pharmaceuticals Corporation.
Faculty/Planner
Caroline Robert, MD, PhD
Head, Dermatology Unit
Director, Melanoma Research Team at INSERM U981
Gustave Roussy and Paris Saclay University
Villejuif, France
Caroline Robert, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; F. Hoffmann-La Roche Ltd.; MSD; Novartis Pharmaceuticals Corporation; Pierre Fabre Group; Pfizer; and Sanofi.
Faculty/Planner
Ahmad A. Tarhini, MD, PhD
Senior Member, Departments of Cutaneous Oncology & Immunology
H. Lee Moffitt Cancer Center & Research Institute
Professor, Department of Oncologic Sciences
University of South Florida Morsani College of Medicine
Chair, ORIEN Scientific Committee & ImmunoOncology Research Subcommittee
Tampa, Florida
Ahmad A. Tarhini, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for BioNTech SE; Bristol Myers Squibb; Clinigen Limited; Eisai, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Instil Bio; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Partner Therapeutics, Inc.; Regeneron Pharmaceuticals Inc.; and Sanofi.
Grant/Research Support from Acrotech Biopharma; Agenus Inc.; Bristol Myers Squibb; Checkmate Pharmaceuticals; Clinigen Limited; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Nektar Therapeutics; OncoSec Medical Incorporated; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute
for Medical Education, is jointly accredited by the Accreditation Council for
Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy
Education (ACPE), and the American Nurses Credentialing Center (ANCC), to
provide continuing education for the healthcare team.Support
This activity is supported through an educational grant from Bristol Myers Squibb.Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.MOC Statement
Successful completion of this CME activity, which includes
participation in the evaluation component, enables the participant to earn up
to 1.0 MOC points and patient safety MOC credit in the American Board of
Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is
the CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.Universal Activity Number: JA4008289-0000-22-012-H01-P
Type of Activity: Knowledge
Interprofessional Continuing Education (IPCE) Statement
This
activity was planned by and for the healthcare team, and learners will
receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning
and change.Method of Participation
There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.Copyright © 2000-2022, PeerView
Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: Impact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy
StartThis activity expired on July 2, 2023; credit is no longer available.
Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: Impact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy
Media: Enduring Material
Activity Release Date: June 3, 2022
Activity Expiration Date: July 2, 2023
Time to Complete Activity: 60 minutes
Activity Description
For individuals with multiple sclerosis (MS), “invisible symptoms” that
include cognitive changes and fatigue exacerbate the burden of disease.
Emerging evidence indicates that in addition to providing high efficacy,
safety, tolerability, and patient convenience, sphingosine 1-phosphate
receptor (S1PR) modulators may yield important benefits related to loss of
cortical gray matter and whole brain volume, addressing cognition as well as
multiple other aspects of MS.
At a recent live event, our expert faculty reviewed the mechanism of action
of S1PR modulators and their important role in MS care, with a focus on the
clinically relevant distinctions among members of this class—from
first-generation fingolimod to the more recently introduced siponimod,
ozanimod, and ponesimod. The faculty discussed the role of agent-specific
characteristics such as relative selectivity and off-target effects in
individualized treatment planning—reviewing key trial data on patient
outcomes and concluding with a case-based workshop addressing treatment
selection, shared decision-making, and COVID-19 vaccination.
Target Audience
This activity has been designed to meet the educational needs of neurologists, internal and family medicine physicians, physician assistants, nurse practitioners, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Discuss the rationale for the modulation of S1P function as a therapeutic approach in multiple sclerosis (MS) in the context of disease pathophysiology
- Individualize S1PR modulator therapy for patients with MS based on the latest evidence on safety, efficacy, and the potential impact on physical and cognitive outcomes
- Apply a patient-centered, team-based approach to treatment selection and sequencing in MS based on the patient’s disease activity, treatment preferences and goals, and therapeutic options
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Bruce Cree, MD, PhD, MAS
George A. Zimmermann Endowed Professor in Multiple Sclerosis
Professor of Clinical Neurology
Clinical Research Director
UCSF Weill Institute for Neurosciences
Department of Neurology
University of California San Francisco
San Francisco, California
Bruce Cree, MD, PhD, MAS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Atara
Biotherapeutics, Inc.; Autobahn Therapeutics; Avotres, Inc.; Biogen; EMD
Serono, Inc.; Horizon Therapeutics plc; Neuron23; Novartis Pharmaceuticals
Corporation; sanofi-aventis U.S. LLC; TG Therapeutics; and Therini Bio,
Inc.
Grant/Research Support from Genentech, Inc.
Faculty/Planner
Heidi Crayton, MD
Medical Director
Multiple Sclerosis Center of Greater Washington
Vienna, Virginia
Heidi Crayton, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Atara Biotherapeutics, Inc.; Biogen;
EMD Serono, Inc.; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S.
LLC; and TG Therapeutics, Inc.
Grant/Research Support from Atara Biotherapeutics, Inc.; Biogen; EMD
Serono, Inc.; Genentech, Inc.; Novartis Pharmaceuticals Corporation; and
sanofi-aventis U.S. LLC.
Speakers Bureau participant with Atara Biotherapeutics, Inc.;
Biogen; EMD Serono, Inc.; Novartis Pharmaceuticals Corporation;
sanofi-aventis U.S. LLC; and TG Therapeutics, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
|
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-017-L01-P
Type of Activity: Knowledge
Interprofessional Continuing Education (IPCE) Statement
|
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on July 2, 2023; credit is no longer available.
Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: Impact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy
Media: Enduring Material
Activity Release Date: June 3, 2022
Activity Expiration Date: July 2, 2023
Time to Complete Activity: 60 minutes
Activity Description
For individuals with multiple sclerosis (MS), “invisible symptoms” that
include cognitive changes and fatigue exacerbate the burden of disease.
Emerging evidence indicates that in addition to providing high efficacy,
safety, tolerability, and patient convenience, sphingosine 1-phosphate
receptor (S1PR) modulators may yield important benefits related to loss of
cortical gray matter and whole brain volume, addressing cognition as well as
multiple other aspects of MS.
At a recent live event, our expert faculty reviewed the mechanism of action
of S1PR modulators and their important role in MS care, with a focus on the
clinically relevant distinctions among members of this class—from
first-generation fingolimod to the more recently introduced siponimod,
ozanimod, and ponesimod. The faculty discussed the role of agent-specific
characteristics such as relative selectivity and off-target effects in
individualized treatment planning—reviewing key trial data on patient
outcomes and concluding with a case-based workshop addressing treatment
selection, shared decision-making, and COVID-19 vaccination.
Target Audience
This activity has been designed to meet the educational needs of neurologists, internal and family medicine physicians, physician assistants, nurse practitioners, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Discuss the rationale for the modulation of S1P function as a therapeutic approach in multiple sclerosis (MS) in the context of disease pathophysiology
- Individualize S1PR modulator therapy for patients with MS based on the latest evidence on safety, efficacy, and the potential impact on physical and cognitive outcomes
- Apply a patient-centered, team-based approach to treatment selection and sequencing in MS based on the patient’s disease activity, treatment preferences and goals, and therapeutic options
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Bruce Cree, MD, PhD, MAS
George A. Zimmermann Endowed Professor in Multiple Sclerosis
Professor of Clinical Neurology
Clinical Research Director
UCSF Weill Institute for Neurosciences
Department of Neurology
University of California San Francisco
San Francisco, California
Bruce Cree, MD, PhD, MAS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Atara
Biotherapeutics, Inc.; Autobahn Therapeutics; Avotres, Inc.; Biogen; EMD
Serono, Inc.; Horizon Therapeutics plc; Neuron23; Novartis Pharmaceuticals
Corporation; sanofi-aventis U.S. LLC; TG Therapeutics; and Therini Bio,
Inc.
Grant/Research Support from Genentech, Inc.
Faculty/Planner
Heidi Crayton, MD
Medical Director
Multiple Sclerosis Center of Greater Washington
Vienna, Virginia
Heidi Crayton, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Atara Biotherapeutics, Inc.; Biogen;
EMD Serono, Inc.; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S.
LLC; and TG Therapeutics, Inc.
Grant/Research Support from Atara Biotherapeutics, Inc.; Biogen; EMD
Serono, Inc.; Genentech, Inc.; Novartis Pharmaceuticals Corporation; and
sanofi-aventis U.S. LLC.
Speakers Bureau participant with Atara Biotherapeutics, Inc.;
Biogen; EMD Serono, Inc.; Novartis Pharmaceuticals Corporation;
sanofi-aventis U.S. LLC; and TG Therapeutics, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
|
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-017-L01-P
Type of Activity: Knowledge
Interprofessional Continuing Education (IPCE) Statement
|
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
Innovations and Imaging in Multiple Sclerosis: Examining the Evidence, Looking Toward the Future of Bruton Tyrosine Kinase Inhibitors
StartThis activity expired on July 1, 2023; credit is no longer available.
Innovations and Imaging in Multiple Sclerosis: Examining the Evidence, Looking Toward the Future of Bruton Tyrosine Kinase Inhibitors
Media: Enduring Material
Activity Release Date: June 2, 2022
Activity Expiration Date: July 1, 2023
Time to Complete Activity: 60 minutes
Activity Description
Bruton tyrosine kinase (BTK) inhibitors show great promise in the quest to
identify additional novel interventions to address multiple sclerosis (MS)
pathophysiology and help to individualize care. Four BTK
inhibitors—evobrutinib, tolebrutinib, fenebrutinib, and remibrutinib—are in
phase 3 clinical trials for relapsing and/or progressive MS, based on the
potential of these agents to affect processes mediated by B cells and myeloid
cells (eg, microglia), which may contribute to inflammation and
neurodegeneration.
At a recent live CME/NCPD/CPE event, a panel of expert physicians highlighted
the rationale for using BTK inhibitors to treat MS, assessed the latest data
from completed and ongoing clinical trials, and reviewed
guideline-recommended protocols for patient imaging. In addition to the
lively discussion, animated video abstracts further illustrated these
topics.
Target Audience
This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the rationale for inhibiting Bruton tyrosine kinase (BTK) to treat multiple sclerosis (MS)
- Evaluate current evidence related to the efficacy, safety, and tolerability of BTK inhibitors in the treatment of MS
- Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities
- Implement guideline-recommended imaging protocols to assess disease activity and monitor treatment response in patients with MS
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Benjamin M. Greenberg, MD, MHS
Vice Chair of Clinical and Translational Research
Department of Neurology
University of Texas Southwestern Medical Center
Dallas, Texas
Benjamin M. Greenberg, MD, MHS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; EMD
Serono, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Genzyme; Horizon
Therapeutics plc; Immunovant, Inc.; IQVIA Inc.; Novartis Pharmaceuticals
Corporation; Sandoz AG; and Signant Health.
Grant/Research Support from Anokion US Inc.; Clene Inc.; and
Regeneron Pharmaceuticals Inc.
Other Financial or Material Support from GenrAB in an executive
role/ownership interest.
Co-Chair/Planner
Professor Anthony Traboulsee, MD
Research Chair of the MS Society
Division of Neurology, Department of Medicine
The University of British Columbia
Vancouver, British Columbia, Canada
Professor Anthony Traboulsee, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Biogen; EMD Serono, Inc.; F.
Hoffmann-La Roche Ltd; Novartis AG; and Sanofi Genzyme.
Grant/Research Support from F. Hoffmann-La Roche Ltd and Sanofi
Genzyme.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
|
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Sanofi.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.8 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-018-L01-P
Type of Activity: Knowledge
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on July 1, 2023; credit is no longer available.
Innovations and Imaging in Multiple Sclerosis: Examining the Evidence, Looking Toward the Future of Bruton Tyrosine Kinase Inhibitors
Media: Enduring Material
Activity Release Date: June 2, 2022
Activity Expiration Date: July 1, 2023
Time to Complete Activity: 60 minutes
Activity Description
Bruton tyrosine kinase (BTK) inhibitors show great promise in the quest to
identify additional novel interventions to address multiple sclerosis (MS)
pathophysiology and help to individualize care. Four BTK
inhibitors—evobrutinib, tolebrutinib, fenebrutinib, and remibrutinib—are in
phase 3 clinical trials for relapsing and/or progressive MS, based on the
potential of these agents to affect processes mediated by B cells and myeloid
cells (eg, microglia), which may contribute to inflammation and
neurodegeneration.
At a recent live CME/NCPD/CPE event, a panel of expert physicians highlighted
the rationale for using BTK inhibitors to treat MS, assessed the latest data
from completed and ongoing clinical trials, and reviewed
guideline-recommended protocols for patient imaging. In addition to the
lively discussion, animated video abstracts further illustrated these
topics.
Target Audience
This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the rationale for inhibiting Bruton tyrosine kinase (BTK) to treat multiple sclerosis (MS)
- Evaluate current evidence related to the efficacy, safety, and tolerability of BTK inhibitors in the treatment of MS
- Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities
- Implement guideline-recommended imaging protocols to assess disease activity and monitor treatment response in patients with MS
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Benjamin M. Greenberg, MD, MHS
Vice Chair of Clinical and Translational Research
Department of Neurology
University of Texas Southwestern Medical Center
Dallas, Texas
Benjamin M. Greenberg, MD, MHS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; EMD
Serono, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Genzyme; Horizon
Therapeutics plc; Immunovant, Inc.; IQVIA Inc.; Novartis Pharmaceuticals
Corporation; Sandoz AG; and Signant Health.
Grant/Research Support from Anokion US Inc.; Clene Inc.; and
Regeneron Pharmaceuticals Inc.
Other Financial or Material Support from GenrAB in an executive
role/ownership interest.
Co-Chair/Planner
Professor Anthony Traboulsee, MD
Research Chair of the MS Society
Division of Neurology, Department of Medicine
The University of British Columbia
Vancouver, British Columbia, Canada
Professor Anthony Traboulsee, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Biogen; EMD Serono, Inc.; F.
Hoffmann-La Roche Ltd; Novartis AG; and Sanofi Genzyme.
Grant/Research Support from F. Hoffmann-La Roche Ltd and Sanofi
Genzyme.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
|
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Sanofi.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.8 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-018-L01-P
Type of Activity: Knowledge
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
